Last Price
17.47
Today's Change
+0.17 (0.98%)
Day's Change
17.46 - 18.72
Trading Volume
882,194
Market Cap
1 Billion
Shares Outstanding
91 Million
Avg Volume
567,323
Avg Price (50 Days)
16.17
Avg Price (200 Days)
16.45
PE Ratio
-5.62
EPS
-3.11
Earnings Announcement
05-Nov-2024
Previous Close
17.30
Open
18.47
Day's Range
17.46 - 18.72
Year Range
12.95 - 20.31
Trading Volume
898,661
1 Day Change
0.98%
5 Day Change
15.01%
1 Month Change
11.13%
3 Month Change
26.23%
6 Month Change
2.95%
Ytd Change
-11.23%
1 Year Change
6.46%
3 Year Change
-44.50%
5 Year Change
114.88%
10 Year Change
2.76%
Max Change
2.76%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.